Stoke Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Stoke Therapeutics's estimated annual revenue is currently $19.1M per year.
- Stoke Therapeutics's estimated revenue per employee is $164,353
- Stoke Therapeutics's total funding is $235.1M.
- Stoke Therapeutics's current valuation is $720.4M. (January 2022)
Employee Data
- Stoke Therapeutics has 116 Employees.
- Stoke Therapeutics grew their employee count by 0% last year.
Stoke Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Co-Founder and SVP, Head Discovery Research | Reveal Email/Phone |
2 | CFO | Reveal Email/Phone |
3 | Chief Operating & Business Officer | Reveal Email/Phone |
4 | Chief Human Resources Officer | Reveal Email/Phone |
5 | Chief Commercial Officer | Reveal Email/Phone |
6 | Chief Financial Officer | Reveal Email/Phone |
7 | VP, Controller | Reveal Email/Phone |
8 | VP, Head Investor Relations | Reveal Email/Phone |
9 | Head, Clinical Data Management | Reveal Email/Phone |
10 | SVP, Clinical Development Operations | Reveal Email/Phone |
Stoke Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Stoke Therapeutics?
Stoke is developing antisense oligonucleotide medicines that target RNA splicing to increase gene expression for the treatment of severe genetic diseases.
keywords:N/A
$235.1M
Total Funding
116
Number of Employees
$19.1M
Revenue (est)
0%
Employee Growth %
$720.4M
Valuation
N/A
Accelerator
Stoke Therapeutics News
Bank of America reduced their target price on shares of Stoke Therapeutics from $43.00 to $40.00 and set a buy rating for the company in a...
TANGO (Targeted Augmentation of Nuclear Gene Output) is Stoke's proprietary research platform. Stoke's initial application for this technology...
Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating...
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics today announced that it has completed a $90 million Series B financing to advance its pipeline of antisense oligonucleotide medicines for Dravet Syndrome and other severe genetic diseases. The financing round was led by RTW Investments with pa ...
Stoke Therapeutics, a Bedford, Mass.-based biotechnology company, completed a $90m Series B financing. The round was led by RTW Investments with participation from founding investor Apple Tree Partners and new investors RA Capital Management, Cormorant Asset Management, Perceptive Advisors, fun ...
Other Companies in Bedford
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $18M | 116 | -5% | N/A |
#2 | $29.1M | 116 | -6% | N/A |
#3 | $17.7M | 118 | 7% | N/A |
#4 | $34.5M | 119 | -6% | N/A |
#5 | $42.7M | 121 | -18% | $58M |